Literature DB >> 24756423

ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension.

Ashish Goel1, P L Alagammai, Sukesh C Nair, Ian Mackie, Banumathi Ramakrishna, Jayaprakash Muliyil, Shyamkumar N Keshava, C E Eapen, Elwyn Elias.   

Abstract

BACKGROUND: We have reported A disintegrin and metalloprotease with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency in noncirrhotic intrahepatic portal hypertension (NCIPH) patients of European origin with preserved liver function. We aimed to study ADAMTS13-von Willebrand factor (vWF) imbalance in Indian patients with NCIPH.
METHODS: Twenty-nine cases with NCIPH [22 males; 29 years (13-58); Child's A, 23; B, 6], 22 disease controls with cryptogenic chronic liver disease [15 males; 46 years (18-74); Child's A, 9; B, 9; C, 4] and 17 healthy controls [14 males; 32 years (27-45)] were enrolled in the study. We measured ADAMTS13 antigen and activity (by collagen binding assay (CBA) and by fluorescence resonance energy transfer [FRET] assay), and vWF antigen levels in plasma of study patients.
RESULTS: ADAMTS13 activity by CBA in NCIPH patients (32 %, 5 % to 100 %; median, range; p-value <0.001) and disease controls (36 %, 5 % to 144 %; p = 0.001) was significantly lower than in healthy controls (87 %; 60 % to 148 %). ADAMTS13 antigen and activity by FRET assay were also lower in cases and disease controls. ADAMTS13 activity (by CBA) to antigen ratio was lower in NCIPH and disease controls than in healthy controls. Of 29 NCIPH patients, 3 (all in Child's A) had severe ADAMTS13 deficiency (<10 % ADAMTS13 activity), and 8 (Child's A, 7; B, 1) had moderate ADAMTS13 deficiency (10 % to 25 % activity). Conversely, vWF antigen and vWF:ADAMTS13 ratio were higher in patients with NCIPH and in disease controls than in healthy controls.
CONCLUSIONS: This study validates the finding of ADAMTS13 deficiency in NCIPH despite preserved liver functions in an Indian population suggesting its involvement in pathogenesis of NCIPH.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756423     DOI: 10.1007/s12664-014-0460-4

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  31 in total

Review 1.  ADAMTS-13 assays in thrombotic thrombocytopenic purpura.

Authors:  F Peyvandi; R Palla; L A Lotta; I Mackie; M A Scully; S J Machin
Journal:  J Thromb Haemost       Date:  2010-01-21       Impact factor: 5.824

2.  Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.

Authors:  Ian Mackie; Katy Langley; Andrew Chitolie; Ri Liesner; Marie Scully; Samuel Machin; Flora Peyvandi
Journal:  Thromb Haemost       Date:  2013-01-10       Impact factor: 5.249

3.  Prognostic significance of von willebrand factor in cirrhosis: a possible mechanism.

Authors:  Chundamannil E Eapen; Joshua E Elias; Ian Mackie; Elwyn Elias
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

Review 4.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

5.  Porto-pulmonary hypertension exacerbated by platelet transfusion in a patient with ADAMTS13 deficiency.

Authors:  Joshua E Elias; Ian Mackie; Chundamannil E Eapen; Patrick Chu; Jean C Shaw; Elwyn Elias
Journal:  J Hepatol       Date:  2012-11-10       Impact factor: 25.083

6.  ADAMTS13 is expressed in hepatic stellate cells.

Authors:  Wenhua Zhou; Mari Inada; Tai-Ping Lee; Daniel Benten; Sergey Lyubsky; Eric E Bouhassira; Sanjeev Gupta; Han-Mou Tsai
Journal:  Lab Invest       Date:  2005-06       Impact factor: 5.662

7.  Localization of ADAMTS13 to the stellate cells of human liver.

Authors:  Masahito Uemura; Kouko Tatsumi; Masanori Matsumoto; Masao Fujimoto; Tomomi Matsuyama; Masatoshi Ishikawa; Taka-Aki Iwamoto; Toshio Mori; Akio Wanaka; Hiroshi Fukui; Yoshihiro Fujimura
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

Review 8.  Review article: thrombocytopenia in chronic liver disease.

Authors:  F Poordad
Journal:  Aliment Pharmacol Ther       Date:  2007-11       Impact factor: 8.171

9.  Portal and parenchymal alterations of the liver in idiopathic portal hypertension: a histological and immunochemical study.

Authors:  Koichi Tsuneyama; Wataru Kouda; Yasuni Nakanuma
Journal:  Pathol Res Pract       Date:  2002       Impact factor: 3.250

10.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

View more
  11 in total

1.  Hepatobiliary quiz-12 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12

2.  Noncirrhotic intrahepatic portal hypertension: towards a unifying definition and etiology.

Authors:  B S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2014-05-31

Review 3.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

4.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

5.  Investigation into celiac disease in Indian patients with portal hypertension.

Authors:  Rakhi Maiwall; Ashish Goel; Anna B Pulimood; Sudhir Babji; J Sophia; Chaya Prasad; K A Balasubramanian; Banumathi Ramakrishna; Susy Kurian; G John Fletcher; Priya Abraham; Gagandeep Kang; B S Ramakrishna; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2014-09-18

6.  Arsenicosis, possibly from contaminated groundwater, associated with noncirrhotic intrahepatic portal hypertension.

Authors:  Ashish Goel; Pamela Christudoss; Renu George; Banumathi Ramakrishna; G Jayakumar Amirtharaj; Shyamkumar N Keshava; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Jude J Fleming; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-05-26

7.  ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.

Authors:  Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-05

Review 8.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

9.  Potential danger of isolated platelet transfusion in patients with dengue infection.

Authors:  C E Eapen; S C Nair
Journal:  Indian J Med Res       Date:  2017-02       Impact factor: 2.375

10.  Acute liver injury induced by low dose dimethylnitrosamine alters mediators of hepatic vascular flow.

Authors:  G Jayakumar Amirtharaj; Kavitha R Thangaraj; Archana Kini; Raghupathy V; Ashish Goel; Eapen C E; Aparna Venkatraman; Anna B Pulimood; Balasubramanian K A; Anup Ramachandran
Journal:  Toxicol Rep       Date:  2014-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.